UK-based company that deals with AI-powered early lung disease diagnosis and precision care Optellum announced on Friday that it has achieved ISO 27001:2022 certification.
The certification is claimed to underscore the company's commitment to best practices in information security and robust data protection.
Optellum's CEO, Dr Johnathan Watkins, said, 'As a healthcare technology company, protection of the assets and data of our customers, partners, and employees is non-negotiable. I would like to congratulate our exceptional staff, in particular Massoud and our Information Security team. Their dedication and expertise have made this achievement possible.'
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Dupixent receives approval in Japan as first biologic for COPD treatment
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Actinium Pharmaceuticals signs Ac-225 radioisotope agreement with Eckert & Ziegler
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab
Hikma announces Health Canada approval of KLOXXADO Nasal Spray for opioid overdose treatment
Johnson & Johnson reports breakthrough overall survival data for EGFR-mutated lung cancer treatment
Altesa BioSciences granted US regulatory approval for vapendavir clinical trials
Black Diamond Therapeutics and Servier agree global licensing deal for BDTX-4933
AstraZeneca secures EU approval for Imfinzi in limited-stage small cell lung cancer